EMA starts rapid test procedure – NEUE Vorarlberger Tageszeitung

EMA starts rapid test procedure – NEUE Vorarlberger Tageszeitung

International

TODAY • 12:04 PM
/ 2 minutes reading time

Curevac vaccine: data and results are continuously monitored.

 The  European Medicines Agency EMA has the rapid testing procedure for the vaccine des Tübingen manufacturer Curevac started.

 The  EMA announced this on Friday in Amsterdam.

 The  decision is based on the preliminary results of laboratory tests and clinical studies. According to the EMA, this makes it clear that the vaccine stimulates the production of antibodies against the coronavirus.

 The  authority evaluates the data according to the so-called Rolling review process.

 The  data and results are continuously checked, even if the test series has not yet been completed and no application for approval in the EU has been submitted.

 The  procedure is faster than conventional tests, but just as carefully as the EMA announced. How long the exam will take is unclear.

As soon as there is enough evidence that the vaccine is effective, the manufacturer can apply for marketing authorization in the EU.

 The  EMA experts give a recommendation on this.

 The  EU Commission then makes a formal decision. Two other vaccine testing procedures are currently underway. So far, three vaccines have been approved in the EU.

Share Button

Add a Comment

Your email address will not be published. Required fields are marked *